Search Results

You are looking at 251 - 260 of 2,910 items for :

  • Refine by Access: All x
Clear All
Full access

CGE24-096: Impact of Somatic Mutations on Outcomes of Salvage Radiation and Hormonal Therapy for Prostate Cancer Recurrence After Prostatectomy

Keisuke Otani, David J. Konieczkowski, Daniel J . Rodden, Shulin Wu, Elai Davicioni, Philip J. Saylor, Douglas M. Dahl, Chin-Lee Wu, Sophia C. Kamran, Jason A. Efstathiou, and David T. Miyamoto

) was performed to an average depth of 162X (r, 70.7–219). We tested for association between somatic mutations and clinical outcomes using the log-rank test and Cox proportional hazards model. Results: Median age at salvage was 64.5 yrs. High quality

Full access

HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators

Erin Comerford, Lindsey Norcross, Medha Sasane, Ying Zheng, and Ari Gnanasakthy

Background: Despite increasing inclusion of patient-reported outcomes (PROs) in pivotal trials, PRO data often do not make it into labeling for approved products. This is particularly true in the field of oncology, where assessment and

Full access

CLO23-042: Clinical Outcomes of Radical Radiotherapy With or Without Chemotherapy in Inoperable Locally Advanced Squamous Cell Carcinoma of Oral Cavity

Maria Philip, Jomon Raphael Chalissery, Febin Antony, Rajkrishna B, and Mathew Varghese K

to determine the benefits and overall survival in these patients treated with definitive radiotherapy with or without concurrent chemotherapy. Methods: We conducted a retrospective analysis to evaluate the clinical outcomes in patients with

Full access

HSR24-139: Patient-Reported Outcome Measures Used in Patients With Chronic Phase–Chronic Myeloid Leukemia: A Systematic Review of the Literature

Kathryn E. Flynn, Lovneet Saini, Aditi Kataria, Kejal Jadhav, Daisy Yang, and David Wei

for CML patients in survivorship. Patient-reported outcome (PRO) measures provide key evidence about patients’ experiences with TKIs, as TKIs differ in associated adverse events (AEs) and side effect profiles. What we understand about PROs depends on

Full access

EPR22-111: Outcomes and Utilization of Adjuvant Chemotherapy With and Without an Anthracycline in Node-Positive, Triple-Negative Breast Cancer: Analysis of SEER-Medicare Data

Stephanie Lakritz, Anna Schreiber, Elizabeth Molina, Elisabeth Meyer, Cathy J Bradley, and Jennifer R Diamond

therapy (ATAX) regimens shown to be more efficacious compared to non-anthracycline-containing, taxane-based regimens (TAX) in node-positive disease. However, data investigating outcomes and utilization of adjuvant chemotherapy in older women with node

Full access

HSR22-166: Patient Demographic and Socioeconomic Differences in Non-Small Cell and Small Cell Lung Cancers: Impact on Outcomes. A National Cancer Database Analysis.

Logan Roof, Wei Wei, and James P Stevenson

communities, distance to an academic center, income, insurer, and education level. The goal of this study was to determine whether the same disparities exist in non-small cell lung cancer (NSCLC), and how the patient demographics and outcomes compare to those

Full access

HSR23-114: Clinical Characteristics and Outcomes of US Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients Not Receiving Guideline Preferred Regimens

Daniel Simmons, Yang Xiao, Corina Roca, Zhuoxin Jiang, and Marnie Boron

-preferred regimens and describe their outcomes. Methods: We conducted a retrospective observational cohort study using US electronic health records from Flatiron Health. Patients were diagnosed with ES-SCLC between October 1st 2018 and June 30th 2022 and were

Full access

Counterpoint: Implementing Population Genetic Screening for Lynch Syndrome Among Newly Diagnosed Colorectal Cancer Patients—Will the Ends Justify the Means?

Michael J. Hall

with Lynch in the United States population and, more importantly, 2) to effectively improve health outcomes for patients with CRC and their relatives, because of a paucity of information on real-life access barriers, educational gaps, and patient

Full access

Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study

Baijun Dong, Liancheng Fan, Bin Yang, Wei Chen, Yonghong Li, Kaijie Wu, Fengbo Zhang, Haiying Dong, Huihua Cheng, Jiahua Pan, Yinjie Zhu, Chenfei Chi, Liang Dong, Jianjun Sha, Lei Li, Xudong Yao, and Wei Xue

alterations, especially those involving DDR genes, can predict the clinical outcomes of Chinese patients with mCRPC following specific treatments remains to be fully elucidated. Routine sampling of bone and other metastatic tissues in patients with mCRPC is

Full access

Current Surveillance After Treatment is Not Sufficient for Patients With Rectal Cancer With Negative Baseline CEA

Dingcheng Shen, Xiaolin Wang, Heng Wang, Gaopo Xu, Yumo Xie, Zhuokai Zhuang, Ziying Huang, Juan Li, Jinxin Lin, Puning Wang, Meijin Huang, Yanxin Luo, and Huichuan Yu

sustained negative CEA during surveillance, whereas the other 26 (41.3%) in the CEA-turn group had elevated CEA during surveillance before the recurrent disease was confirmed. Interestingly, when we stratified the overall recurrence outcomes by local and